Completed PHASE4 INTERVENTIONAL 2-arm NCT00518518

Safety and Efficacy of Ultra-Rush Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen

Safety and Efficacy of Ultra-Rush High-Dose Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen - Prospective, Randomized, Placebo Controlled Study.

Sponsor: Medical University of Lodz

Conditions Asthma

Interventions Staloral 300 placebo

Updated 6 times since 2017 Last updated: May 14, 2009 Started: Mar 31, 2006 Primary completion: Nov 30, 2008 Completion: Nov 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Asthma, this trial is completed. The trial is conducted by Medical University of Lodz and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Oct 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Oct 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medical University of Lodz

Data source: Medical University of Lodz

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lodz, Poland